[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiamen Cardiovascular Hospital, Xiamen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644352","early-phase-1-percutaneous-pulmonary-artery-denervation-padn-for-the-treatment-of-pulmonary-hypertension-after-transcatheter-mitral-valve-edge-to-edge-repair-m-teer-a-prospective-cohort-study-100644352",false,"NCT07662655","Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Diagnosed with pulmonary hypertension (defined as mPAP \\>20 mmHg measured by right heart catheterization) at least 3 months after successful M-TEER, having received guideline-directed medical therapy (GDMT) for at least 2 months;\n3. No contraindications for PADN (e.g., anatomical abnormalities of the main pulmonary artery precluding catheter placement, known pulmonary artery stenosis, uncontrolled severe arrhythmias);\n4. Understands and is willing to sign the informed consent form and authorizes the use of health and study-related information;\n5. Willing to comply with the treatment and follow-up schedule required by the protocol\n\nExclusion Criteria:\n\n1. Cardiac index (CI) \\\u003C 1.5 L\u002Fmin\u002Fm²;\n2. Severe renal insufficiency (creatinine clearance rate (CrCL) \\\u003C 30 mL\u002Fmin);\n3. Left ventricular ejection fraction (EF) \\\u003C30% on echocardiography;\n4. Severe hematological disease or severe bleeding tendency (platelet count \\\u003C10×10⁹\u002FL; severe and extensive bleeding; suspected or confirmed intracranial hemorrhage);\n5. Systemic inflammatory disease, malignancy, tricuspid valve stenosis, pulmonary artery stenosis, and other cardiac diseases requiring surgical or interventional treatment;\n6. Acute systemic infectious disease;\n7. Poor general condition due to various systemic diseases;\n8. Pulmonary veno-occlusive disease;\n9. Cachexia;\n10. Diagnosed with WHO Group 1, 3, 4, or 5 pulmonary hypertension;\n11. Anticipated to undergo other surgical or interventional procedures within 6 months;\n12. Life expectancy \\\u003C12 months;\n13. Allergy to the drugs or metal materials used in the study;\n14. Women who are breastfeeding, pregnant, or planning to become pregnant within one year;\n15. Participation in another drug or medical device clinical trial within 3 months prior to screening;\n16. Any condition deemed unsuitable for participation in this clinical trial by the investigator. \\|","ALL","18 Years","80 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making",[26,27],"Pulmonary Hypertension","Pulmonary Hypertension Associated With HFpEF","RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":32},"2026-06-06",{"date":36,"type":20},"2028-08-31",{"name":38,"class":39},"Xiamen Cardiovascular Hospital, Xiamen University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100597240","structural-heart-surgery-assist-system-for-transcatheter-mitral-valve-edge-to-edge-repair-teer-100597240","NCT07055919","Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).","A Prospective, Multicenter, Stratified Randomized Controlled, Non-Inferiority Clinical Trial to Evaluate the Safety and Efficacy of the Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender.\n2. Symptomatic moderate-to-severe or greater mitral regurgitation (MR ≥3+) confirmed by transthoracic and\u002For transesophageal echocardiography (TTE\u002FTEE), with planned transcatheter edge-to-edge repair (TEER):\n\n   For degenerative mitral regurgitation (DMR):\n\n   -Deemed high-risk for surgical intervention by the heart team:STS score ≥8% for mitral valve replacement (MVR) mortality risk; ≥6% for mitral valve repair mortality risk; OR presence of ≥2 frailty indices (moderate-to-severe frailty); OR anatomical\u002Ftechnical barriers to surgery; OR ≥2 major organ dysfunctions unlikely to improve postoperatively; OR other high-risk factors per heart team assessment.OR patient declines surgery.\n\n   For functional mitral regurgitation (FMR):\n   * Persistent heart failure symptoms (NYHA Class III\u002FIVa) despite guidelines directed medical therapy (GDMT), revascularization, or cardiac resynchronization therapy (CRT) for 1-3 months.\n   * ≥1 hospitalization for heart failure within the past 12 months and\u002For BNP \\>150 pg\u002FmL or NT-proBNP \\>600 pg\u002FmL.\n   * Left ventricular ejection fraction (LVEF) ≥20% and ≤50%, with left ventricular end-systolic diameter (LVESD) ≤70 mm.\n3. Primary regurgitant jet is non-commissural and deemed treatable by the investigator (secondary jets, if present, must be clinically insignificant).\n4. Volunteerly provides informed consent, understands the trial objectives, and agrees to comply with follow-up.\n\nExclusion Criteria:\n\n1. Rheumatic mitral valve disease.\n2. Uncorrected active infection.\n3. Severe calcification or thickening in the clip coaptation zone, rendering TEER anatomically unsuitable.\n4. Intracardiac mass, thrombus, or vegetation on echocardiography.\n5. Severe right heart dysfunction (e.g., lower extremity edema with elevated jugular venous pressure and hepatomegaly) or severe pulmonary hypertension (echocardiographic systolic pulmonary artery pressure \\>70 mmHg).\n6. Severe left heart dysfunction (LVEF \\\u003C20%).\n7. Acute myocardial infarction (AMI) within 30 days prior to the procedure.\n8. Recent CABG, PCI, or TAVR within 30 days prior to the procedure.\n9. Planned tricuspid\u002Faortic valve or major vascular intervention within 30 days post-procedure.\n10. Prior surgical or transcatheter mitral valve repair\u002Freplacement.\n11. Thrombosis in access vessels (e.g., femoral vein, inferior vena cava) impeding catheter advancement.\n12. Stroke\u002FTIA within 30 days or severe carotid stenosis (\\>70% by ultrasound).\n13. Cardiomyopathies or conditions including hypertrophic, restrictive, or infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis, sarcoidosis), constrictive pericarditis, or active endocarditis.\n14. Hemodynamic instability: Systolic blood pressure \\\u003C90 mmHg without afterload-reducing agents, cardiogenic shock, requirement for intra-aortic balloon pump (IABP) or hemodynamic support.\n15. Implanted pacemaker, CRT, or ICD within 30 days prior to the procedure.\n16. End-stage heart failure (ACC\u002FAHA Stage D), post-heart transplant, or listed for transplant.\n17. Hypersensitivity or contraindications: ntolerance to anticoagulants, antiplatelet agents, or anesthesia, allergy to mitralclip materials (nickel\u002Ftitanium, cobalt, chromium, polyester), severe contrast allergy precludes intervention.\n18. Pregnant or breastfeeding.\n19. Participation in other clinical trials (drug\u002Fdevice) without meeting primary endpoints.\n20. Other contraindications per investigator judgment.",{"count":49,"type":20},112,[51],"NA","This trial aims to evaluate the safety and efficacy of the Structural Heart Surgery Assist System in assisting TEER for patients with moderate-to-severe or greater degenerative or functional mitral regurgitation (MR ≥3+). A prospective, multicenter, stratified randomized controlled design with non-inferiority comparison will be used. The experimental group will utilize the Structural Heart Surgery Assist System, while the control group will undergo manual TEER (e.g., MitraClip G4).",[54,55],"Mitral R","Mitral Regurgitation","2025-07-02",{"date":58,"type":32},"2025-07-09",{"date":60,"type":32},"2025-03-22",{"date":62,"type":20},"2026-04-22",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100557032","optimized-strategies-for-malperfusion-syndrome-100557032","NCT06532838","Optimized Strategies for Malperfusion Syndrome","Optimized Strategies for Acute Type A Aortic Dissection Complicated With MalPerfusion Syndrome (OPTIMIZE-MPS)","Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures;\n* Acute type A aortic dissection is confirmed by computed tomography angiography;\n* The symptoms onset within 2 weeks;\n* Patients are diagnosed with ATAAD, with a new diagnosis of malperfusion syndrome ,by meeting both of the following criteria:\n\n  1. Radiographic findings reveal occlusion of the corresponding arteries (including either coronary artery, either carotid artery, celiac trunk, superior mesenteric artery or either iliac artery);\n  2. Clinical features of end organ ischemia (altered consciousness, paralysis, melena, abdominal pain, tenderness to palpation, loss of sensory or motor function of the lower extremities) OR laboratory findings suggestive of end organ ischemia (elevated cardiac enzymes, lactate, myoglobin, or creatine kinase).\n\nExclusion Criteria:\n\n* Age \\\u003C18 yr and \\>80 yr;\n* Unstable condition with cardiac tamponade or aortic rupture on admission;\n* Multiple types of malperfusion syndrome on admission;\n* Bloody stools or melena on admission;\n* Bilaterally fixed dilated pupils, hemorrhagic infarction or herniation of brain on admission;\n* Cardiopulmonary arrest and required continuous uninterrupted cardiopulmonary resuscitation on admission;\n* Irreversible multiple organ failure on admission;\n* Life expectancy \\\u003C 1 year;\n* Patients and (or) their families refused surgery;",{"count":72,"type":20},236,[51],"An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with acute type A aortic dissection (ATAAD) and malperfusion syndrome (MPS).\n\nObjectives: The present study aimed to investigate the difference in all-cause mortality after optimized treatment strategies (OTS) versus traditional treatment strategies (TTS) for ATAAD patients with MPS.\n\nBackground: The mortality of ATAAD with MPS is high. However, the management strategies of MPS patients still not to be confirmed. Compare with TTS, OTS as a strategy for ATAAD patients with MPS might have be beneficial results.",[76],"Aortic Dissection",[78,79,80,81,82],"Malperfusion syndrome","Aortic dissection","Optimized strategies","Central repair","Endovascular reperfusion","NOT_YET_RECRUITING","2024-07-31",{"date":86,"type":32},"2024-08-01",{"date":86,"type":20},{"date":89,"type":20},"2026-10-30",{"name":38,"class":39},""]